Latest stories on SRPT
Sarepta Therapeutics climbs 10%, rebounding from recent slide
Seeking Alpha58 · neutralgeneral
H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target
Investing.com Analyst Ratings28 · bearishanalyst
NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy
Stocktwits News22 · bearishearnings
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook
Investing.com Analyst Ratings56 · neutralanalyst
Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’
The Fly48 · neutralanalyst
Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone
The Fly58 · neutralanalyst
H.C. Wainwright reiterates Sell on Sarepta after Novartis study miss
The Fly28 · bearishanalyst
Mizuho reiterates Sarepta stock rating after Novartis trial miss
Investing.com Analyst Ratings38 · neutralanalyst
Why is Sarepta Therapeutics stock sliding today?
Investing.com Markets34 · bearishgeneral
Novartis drops 13% on trial failure, dragging Dyne and Sarepta
Seeking Alpha28 · bearishproduct/pr
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
StockTitan56 · neutralgeneral
Sarepta: A Prove-It Story Now Defined By ELEVIDYS Execution
Seeking Alpha48 · neutralanalyst
SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’
Stocktwits News67 · bullishproduct/pr
Sarepta (SRPT) Q2 2026 Earnings Call Transcript
Yahoo Finance34 · bearishearnings
Sarepta (SRPT) Q2 2026 Earnings Call Transcript
The Motley Fool34 · bearishearnings
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
TipRanks53 · neutralearnings
Sarepta forecasts $1.2B-$1.3B 2026 net product revenue as Cohort 8 12-week data shifts to Q1 2027
Seeking Alpha67 · bullishearnings
Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Sarepta Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary
Yahoo Finance50 · neutralearnings
Sarepta Therapeutics, Inc. (SRPT) files 8-K
SEC 8-K50 · neutralgeneral
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
StockTitan55 · neutralearnings